Posted by Michael Wonder on 31 Jan 2024
Lilly's Olumiant (baricitinib) now authorised in Canada for adults with severe alopecia areata
30 January 2024 - 17-22% of patients taking Olumiant 2 mg/day and 32-35% of patients taking Olumiant 4 mg/day achieved 80% or more scalp hair coverage, compared to 3-5% taking placebo.
Eli Lilly Canada announced today that Olumiant (baricitinib) received regulatory approval for its severe alopecia areata indication via notice of compliance from Health Canada.
